期刊文献+

糖尿病周围神经病变发病机制研究 被引量:28

Research of the pathogenesis of diabetic peripheral neuropathy
下载PDF
导出
摘要 糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)是糖尿病最常见的慢性并发症之一。根据国际糖尿病联盟的最新统计,2013年全球20-79岁成年人的糖尿病患病率为8.3%,患者人数已达3.82亿,预计到2035年,患者人数将达5.92亿。中国糖尿病患者数为9 840万,居全球首位,到2035年将达1.43亿。无论1型或2型糖尿病,DPN发生率均很高,据调查60%-90%的糖尿病患者发生DPN。目前非外伤性截肢患者的50%-75%由DPN造成。近年来,研究认为DPN是由多种因素包括遗传因素引起糖、脂肪、蛋白质代谢紊乱、血管异常、神经营养因子缺乏、氧化应激及免疫损伤所致,本文综述DPN的病因及可能的发病机制。 Diabetic peripheral neuropathy(DPN) is one of the most common chronic complications of diabetes. According to the latest statistics of the International Diabetes Federation, the global prevalence of diabetes for the adults aged 20 to 79 was 8.3% in 2013 and the number of the patients reached 382 million, and will reach 592 million by 2035. The number of the diabetic patients was 98.4 million in China, ranking first in the world, and it will reach 143 million by 2035. Whether type 1 or type 2 diabetes, the incidence of DPN is high. According to the survey, 60% to 90% of the diabetic patients had DPN. Currently, 50% to 75% of the patients with non-traumatic amputation are due to DPN. In recent years, the research suggests that DPN is caused by many factors, including sugar, fat and protein metabolic disorders, vascular abnormalities, neurotrophic factors deficiency, oxidative stress and immune damage. This article reviews the etiologies and possible mechanisms of DPN.
作者 施晓红
出处 《上海医药》 CAS 2016年第2期3-7,共5页 Shanghai Medical & Pharmaceutical Journal
基金 上海市卫生和计划生育委员会面上项目(201540075) 上海市金山区卫生局科研项目(2011-07)
关键词 糖尿病 周围神经病变 氧化应激 炎症 肿瘤坏死因子 diabetes diabetic peripheral neuropathy oxidative stress inflammation tumor necrosis factor
  • 相关文献

参考文献18

  • 1Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103(2): 137-149.
  • 2李颖,李刚,冯波.糖尿病周围神经病变的诊治进展[J].中国糖尿病杂志,2013,21(9):769-772. 被引量:54
  • 3Lappas M, Permezel M, Rice GE. Advanced glycation end products mediate pro-inflammatory actions in human gestational tissues via nuclear factor-kappa B and extracellular signal-regulated kinase 1/2[J]. J Endocrinol, 2007, 193(2): 269-277.
  • 4Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet[J]. JAm Diet Assoc, 2010, 110(6): 911-916.
  • 5Slow YL, Au-Yeung KK, Woo CW, et al. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes viaprotein kinase C beta activation[J]. Biochem J, 2006, 398(1): 73-82.
  • 6Xu J, Weng YI, Simonyi A, et al. Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachadonic acid release in primary murine astrocytes[J]. J Neurochem, 2002, 83(2):259-270.
  • 7Vincent AM, Russell JW, Low P, et al. Oxidative stress in the pathogenesis of diabetic neuropathy[J]. Endocr Rev, 2004, 25(4): 612-628.
  • 8Rask CA. Biological actions of nerve growth factor in the peripheral nervous system[J]. Eur Neurol, 1999, 41(Suppl 1): 14-19.
  • 9R6sen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society[J]. Diabetes Metab Res Rev, 2001, 17(3): 189-212.
  • 10Apfel SC. Neurotrophic factors and diabetic peripheral neuropathy[J]. Eur Neurol, 1999, 41(suppl 1): 27-34.

二级参考文献35

  • 1Young MJ,Boulton AJ,Mac Leod AF. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population[J].{H}DIABETOLOGIA,1993.150-154.
  • 2Feldman EL,Stevens MJ,Thomas PK. A practical twostep quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy[J].{H}DIABETES CARE,1994.12811289.
  • 3Perkins BA,Bril V,Olaleye D. Simple screening tests for peripheral neuropathy in the diabetes clinic[J].{H}DIABETES CARE,2001.250-256.
  • 4Mete T,Aydin Y,Saka M. Comparison of efficiencies of michigan neuropathy screening instrument,neurothesiometer,and electromyography for diagnosis of diabetic neuropathy[J].Int J Endocrinol,2013.821745.
  • 5Papanas N,Boulton AJ,Malik RA. A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy[J].{H}Diabetic Medicine,2013.525-534.
  • 6Pananas N,Papatheodorou K,Papazoglou D. A comparison of the new indicator test for sudomotor function (Neuropad) with the Vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in sub jects with type 2 diabetes[J].Exp Clin Endorinol Diabetes,2008.135-138.
  • 7Quattrini C,Jeziorska M,Tavakoli M. The Neuropad test:a visual indicator test for human diabetic neuropathy[J].{H}DIABETOLOGIA,2008.1046-1050.
  • 8Pananas N,Papatheodorou K,Papazoglou D. A prospective study on the use of the indicator test neuropad for the early diagnosis of peripheral neuropathy in type 2 diabetes[J].Exp Clin Endorinol Diabetes,2011.122-125.
  • 9Tentonouris N,Achtsidis V,Marinous K. Evaluation of the self-administered indicator plaster neuropad for the diagnosis of neuropathy in diabetes[J].{H}DIABETES CARE,2008.236-237.
  • 10Yoshioka K,Okada H. Useful application of the neuropad test for assessment of diabetic polyneuropathy[J].{H}Internal Medicine,2012.3241-3245.

共引文献53

同被引文献327

引证文献28

二级引证文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部